交易中 11-18 10:57:05 美东时间
-0.380
-1.26%
Viridian Therapeutics reports positive Phase 1 data for VRDN-008, demonstrating prolonged IgG suppression with dosing every 8 weeks in myasthenia gravis.
11-10 00:55
US stocks up, Dow gains 200 points, NASDAQ slightly up. Utilities rise, industrials fall. Americas Gold and Silver Corp shares down 13% after earnings.
03-30 22:25
The Q4 earnings report for Viridian Therapeutics (NASDAQ:VRDN) was released on ...
02-26 20:24
William Blair starts coverage of Viridian, citing veligrotug's advantages over Tepezza and key 2026 catalysts, including FDA review and VRDN-003 Phase 3 data.
2025-12-04 04:25
对于以“创新七君”为代表的中国头部Biotech来说,已在2024年年报披露时普遍站上盈亏平衡线,2025年则不再是验证能否盈利的一年,而是走进拐点的新周期...
2025-08-13 21:59
Analysts' ratings for Viridian Therapeutics (NASDAQ:VRDN) over the last quarter...
2024-09-27 02:00
- THRIVE global phase 3 clinical trial evaluated efficacy and safety of VRDN-001 in patients with active thyroid eye disease (TED) -- Conference call and webcast to be held Tuesday, September 10, at 8:00 a.m. ET -
2024-09-10 04:03
RBC Capital analyst Gregory Renza reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and maintains $35 price target.
2024-08-28 20:53
HC Wainwright & Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $27 price target.
2024-08-15 18:23